OSE Pharma, bientôt OSE Immunotherapeutics? - ACHAT - OC 13€
OSE Pharma et Effimune ont annoncé hier après marché leur projet de fusion. Deux Assemblées Générales Extraordinaires sont attendues fin du T2 pour valider ce projet. Si celui-ci est confirmé, cette fusion réduirait la part des actionnaires d’OSE Pharma à 71% du Capital de cette nouvelle entité. Malgré la dilution, nous voyons ce projet comme une excellente nouvelle pour la société qui met la main sur un portefeuille produits (certes à un stade précoce) extrêmement prometteur. En effet, soulignons tout particulièrement son anti CD28 en phase I et dont nous attendons pour le T3 de cette année la prise en licence par Janssen. Avec un portefeuille produits qui pourrait potentiellement s’accroître, nous maintenons notre recommandation à ACHAT. Nous maintenons également notre objectif de cours à 13€ en attendant la validation de ce projet.Ose Immunotherapeutics SA, formerly Orphan Synergy Europe Pharma SA, is a France-based company principally engaged in the clinical stage biotechnological sector. The Company develops immunotherapy products against invasive or metastatic late-stage cancers. The Company offers a technology, called Memopi, which helps the immune system to eliminate malignant cells; it re-educates the body's immunological memory so that the immune system (and particularly T cytotoxic cells) attacks tumor cells by increasing the patient's specific cytotoxic T response against their cancer. The Company's main product, Texopi, is a patented combination of ten epitopes, selected and optimized from five tumor associated antigens.
Since 2006, Invest Securities has become one of the leading players in investment services for funds and managers, to whom we offer a global and personalised service. Our track record differentiates us and proves our leadership in numerous promising sectors like property and growth companies.
Consisting of 13 different profiles (pharmacist, engineer, financier, etc), the DNA of our financial analysis office is value added and sector expertise. Through daily monitoring and detailed analyses of companies and sectors, we seek to provide a differentiating vision of our 120 stocks followed. Our ideas are circulated every day to nearly 1,000 professionals.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.